Management of newborns with duct-dependent congenital heart disease with prostaglandin E1 – Slovenian guidelines

  • Mojca Grošelj Grenc
  • Maja Pavčnik Arnol
  • Gorazd Kalan
  • Tomaž Podnar
  • Ivan Vidmar

Abstract

Background: Early recognition of duct-dependent congenital heart disease in newborns with duct-dependent pulmonary or systemic blood flow or transposition of the great arteries is critical for early introduction of prostaglandin E1 (PGE1), which allows stabilization of the newborn till cardiac catheterization or surgical intervention. Indications for PGE1, management of newborns with duct-dependent congenital heart disease and interventions in case of side effects of PGE1 are reviewed. Conclusions: It is critical to start with PGE1 infusion as soon as we clinically suspect ductdependent congenital heart disease. With this approach, morbidity and mortality of newborns with congenital heart disease is significantly reduced.

Downloads

Download data is not yet available.
Published
2011-02-01
How to Cite
1.
Grošelj Grenc M, Pavčnik Arnol M, Kalan G, Podnar T, Vidmar I. Management of newborns with duct-dependent congenital heart disease with prostaglandin E1 – Slovenian guidelines. TEST ZdravVestn [Internet]. 1Feb.2011 [cited 15May2024];81(2). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/557
Section
Quality and safety

Most read articles by the same author(s)